Xiaobin Gao's questions to Sanofi SA (SNY) leadership • Q2 2024
Question
An analyst from Barclays, on behalf of Ms. Xiaobin Gao, asked about the development timeline for the COVID-19 and flu combination vaccine with Novavax. They also inquired about its prospects versus solo flu vaccines and the potential synergies with Sanofi's own mRNA flu vaccine candidate.
Answer
Thomas Triomphe, EVP of Vaccines, explained that while specific timelines are not yet public, they aim to begin clinical operations for the combination vaccine in 2024. He stressed the goal is to create a best-in-class product without compromising safety or efficacy. He added that their next-generation mRNA flu program is synergistic, as it aims to improve the standard of care, which is a different approach from competitors.